MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer.
German B, Alaiwi SA, Ho KL, Nanda JS, Fonseca MA, Burkhart DL, Sheahan AV, Bergom HE, Morel KL, Beltran H, Hwang JH, Freedman ML, Lawrenson K, Ellis L.
German B, et al. Among authors: ho kl.
Cancer Res Commun. 2024 Sep 1;4(9):2295-2307. doi: 10.1158/2767-9764.CRC-24-0069.
Cancer Res Commun. 2024.
PMID: 39113611
Free PMC article.